

KEY INFORMATION DOCUMENT

Purpose

This document provides you with key information about this investment product. It is not marketing material. The information is required by law to help you understand the nature, risks, costs, potential gains and losses of this product and to help you compare it with other products.

THAMES VENTURES VCT 2 PLC - HEALTHCARE SHARE CLASS

Product: Healthcare Shares of 0.1 pence each issued by Thames Ventures VCT 2 plc (“Shares”)

ISIN: GB00BDHF5D62

Names of PRIIP manufacturers: Thames Ventures VCT 2 plc (reg. number 06789187) (the “Company”)

Website for the PRIIP manufacturer: www.downing.co.uk/existing-investor/thames-ventures-vct-2

Call this telephone number for more information: +44(0)207 416 7780

Competent Authority of the PRIIP Manufacturer in relation to the KID: UK Financial Conduct Authority

Date of production of this Key Information Document: 13 October 2022

Comprehension alert: You are about to purchase a product that is not simple and may be difficult to understand.

What is this product?

Type: Venture Capital Trust

Objectives: To provide attractive returns to investors by investing in a portfolio of growth investments, at different stages in the business life cycle, and to pay an annual tax-free dividend of at least 4% of NAV.

Bid-offer spread: Shares are bought and sold via markets. Typically, at any given time on any given day, the price you pay for a Share will be higher than the price at which you could sell it.

The recommended holding period: is ten years to allow for underlying investments to mature. The Company is intended to be evergreen and there are no relevant prescribed maturity dates but it is always open for a majority of shareholders to resolve that the Company should be liquidated. If you subscribe for Shares at issue and hold them for less than five years you will lose any tax reliefs for which you may have been eligible in respect of that subscription.

Intended retail investor: a typical investor in the Company will be a UK higher-rate income taxpayer, over 18 years of age and with an investment range of between £5,000 and £200,000 as a lump sum, who is capable of understanding and is comfortable with the risks of VCT investment.

Risk Indicator

The summary risk indicator is a guide to the level of risk of this product compared to other products. It shows how likely it is that the product will lose money because of movements in the markets or because we are not able to pay you.



We have classified this product as 6 out of 7 which is the second highest risk class. This has been calculated using the prescribed methodology, based on historic share price data of appropriate proxies. This rates the potential losses from future performance at a high level, and poor market conditions are very likely to impact the amount you could get back. This is considerably higher than the risk rating shown in the previous KID which arises from a change of methodology such that all VCTs must now have a minimum risk score of 6.

This Product does not include any protection from future market performance, so you could lose some or all of your investment. If we are not able to pay what is owed, you could lose your entire investment. This investment offers no capital guarantee against credit risk. If the underlying companies in which the Company invests do not pay what they owe the Company, you could lose part of the capital you invest (but you do not bear the risk of incurring additional financial obligations or commitments). If you cash in at an early stage, you may not be able to sell your product easily or you may have to sell at a price that significantly impacts on how much you get back. This liquidity risk is not contractual but is due to there being a limited secondary market for shares in venture capital trusts. This investment offers no capital protection against future market performance so you could lose all or part of your investment if you sell in a poor market.

Performance Information

What are the risks and what could I get in return?

The main factors that will affect the performance of the Company are the performance of the healthcare investments in quoted and unquoted companies held within the portfolio; the ability of the Investment Manager to identify and make suitable investments decisions; the ability of the Investment Manager to mitigate counterparty risks and, realise investments; and broader macroeconomic factors that affect the UK market and the valuations of quoted and unquoted investments in the portfolio.

Our forward-looking ex-ante moderate performance scenario return is 5.42% per annum over the recommended holding period. We have used the ex-ante return to model the reduction in yield in our cost calculations below.

Venture Capital Trusts can carry more risk than might be indicated by the Company's share price performance history. Since the Company's Healthcare share class is young – with inception in October 2017 – and has experienced a lack of liquidity over long periods, we have used a liquid daily traded investment proxy in the narrative below.

The proxy used for this Company's Healthcare share class is a blended benchmark of equity indices to reflect the Healthcare Share Pool's sector asset allocation on 31 March 2022. These sectors were dynamically reweighted based on available data to provide a full performance history from 1 January 1999 to 5 October 2022.

The volatility of the Company's returns will vary. Since inception, the Company's Healthcare share class has experienced an annualised volatility of 28.8%. Our proxy has an average annualised volatility of 14.7% over rolling ten-year periods, however during periods of market stress the volatility temporarily increased to 26.0%.

What could affect my return positively?

Specific factors that could affect returns positively would be strong growth of the companies within the portfolio and the ability of the Investment Manager to continually identify and make promising new investments. General factors that affect positive returns for the Shares would be an extended period of UK economic growth and fiscal stability. Increased valuations of the UK Healthcare sector will very likely benefit returns, as the majority of holdings lie within various healthcare subsectors, which make up over 80% of the investment pool's value. Day to day, the proxy's correlations to UK markets is quite low but we would expect larger upward market movements in the UK market to correlate with improvements in valuations in the proxy, and so, the Company's underlying holdings.

In terms of quantitative evidence, the best one-year shareholder return for the proxy was 69.7%. Over the recommended holding period of ten years, the best ten-year rolling performance of the proxy was 15.7% per annum.

What could affect my return negatively?

Specific factors that affect returns negatively would be an underperforming portfolio of quoted and unquoted companies with some holdings possibly defaulting, and a lack of liquidity within the Company to pursue new investments or support existing investments. A breach of the VCT regulations could result in a loss of VCT status and negatively impact returns through the loss of tax reliefs currently available to shareholders. Other factors that affect returns negatively are poor performance of the UK equity markets, in addition, a decrease in the valuations of the UK Healthcare sector is very likely to impact on returns.

In terms of quantitative evidence, the lowest one-year return for the proxy was -29.2%. The lowest ten-year rolling return for the proxy was 2.7% per annum.

What could happen under severely adverse market conditions?

A severe experience could be a loss of 39.8%, which occurred in the proxy from April 2007 to April 2009, it took around a year for the proxy to recover in March 2010. The Company may experience a high proportion of defaults within the portfolio during periods of stress, which could result in you losing all your investment.

What happens if Thames Ventures VCT 2 plc is unable to pay out?

The value of the Shares and the income derived from them is dependent on the performance of the Company's underlying investments and can fluctuate. Investors could lose all or part of their investment. Your capital is at risk. As a shareholder of the Company you would not be able to make a claim to the Financial Services Compensation Scheme about the Company in the event that the Company is unable to pay out.

What are the costs?

The Reduction in Yield (RIY) shows what impact the total costs you pay will have on the investment return you might get. The total costs take into account one-off, ongoing and incidental costs. The amounts shown here are the cumulative costs of the product itself, for three different holding periods. The figures assume you invest £10,000. The figures are estimates and may change in the future.

Costs over time

The person selling you or advising you about this product may charge you other costs. If so, this person will provide you with information about these costs and show you the impact that all costs will have on your investment over time.

Investment Scenarios	If you cash in after 1 year*	If you cash in after 5 years*	If you cash in after 10 years
Total costs	£652	£2,572	£6,672
Impact on return (RIY) per year	6.52%	3.89%	3.56%

*This product cannot be easily realised. This means it is difficult to estimate how much you would get back if you attempt to realise your investment early. You will either be unable to realise your investment early or you will have to pay high costs or make a large loss if you do so. You will also lose tax reliefs gained on subscription if you sell within five years.

Composition of costs

The table below shows the compounding impact each year of the different types of costs on the investment return you might get at the end of the recommended holding period and the meaning of the different cost categories.

This table shows the impact on return per year			
One-off costs	Entry costs	0.33%	Downing LLP will charge a promoter's fee to the Company or either nil or 3.0% of amounts invested depending on the category of investor. We have calculated the impact based on the maximum promoter fee of 3.0%. Stamp duty reserve tax of 0.5% is payable if the Shares are purchased on the secondary market, however this is not included in these calculations.
	Exit costs	0.00%	The Company's costs of buying and selling underlying investments (including costs that borne by those companies). This is an estimate of the expected exposure to such costs.
Ongoing costs	Portfolio transaction costs	0.01%	The impact of the costs of us buying and selling underlying investments for the product.
	Other ongoing costs	3.23%	This represents impact of the costs of running the Healthcare Share Pool each year and includes the fees charged to investee companies by Downing LLP, of 0.27%. The Healthcare Share Pool's annual running costs are capped at 3.3% of its net assets, including a management fee to Downing LLP of 2.5%.
Incidental costs	Performance fees	0.00%	The potential impact of the Performance Incentive arrangements in place.
	Carried interests	0.00%	There are no carried interest arrangements associated with this product.

How long should I hold it and can I take money out early?

The recommended holding period is a minimum of ten years because investing in young growth companies involves a higher degree of risk and volatility, and investments by the Company which prove to be successful may take longer to mature compared to those which prove to be less successful. Investments are likely to be realised by the sale of Shares back to the Company or in the market. The Company has a policy to buy back shares which its shareholders wish to sell, currently at a nil discount to the most recently announced NAV, but its ability to do so may be limited by available cash, the rules of the UKLA, the Companies Act 2006 and the VCT Rules. Accordingly, it is unlikely there will be a liquid market as there is a limited secondary market for shares in VCTs and Investors may find it difficult to realise their investments.

How can I complain?

Complaints about the Company or the key information document should be sent to the company secretary: Mr. Grant Whitehouse, Downing LLP, St. Magnus House, 3 Lower Thames Street, London EC3R 6HD or by email to customer@downing.co.uk or telephone on 020 7416 7780. Website: www.downing.co.uk/complaints

Other relevant information:

Other relevant information relating to Thames Ventures VCT 2 plc can be found in the Prospectus in respect of the Company's Healthcare Share Offer which can be found at:

www.downing.co.uk/existing-investor/thames-ventures-vct-2

The cost, performance and risk calculations included in this KID follow the methodology prescribed by EU rules, as stated in the PRIIPs Regulations and as transposed in UK law in the FCA Handbook. Performance has been calculated using the prescribed methodology, based on historic share price data of appropriate proxies.

Depending on how you buy Shares you may incur other costs, including broker commission, platform fees and Stamp Duty. The distributor will provide you with additional documents where necessary. Prospective investors should note that the value of an investment may go down as well as up and you may not get back the amount originally invested. Therefore, you should only make investments in the fund that you can afford to lose without having any significant impact on your overall financial position or commitments. Taxation levels, bases and reliefs may change if the law changes and the tax benefits of products will vary according to your personal circumstances: independent advice should therefore be sought. Please note that it cannot be guaranteed that the Company's investments will be qualifying companies or that the Company will maintain its qualifying status as a venture capital trust.